HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related...
PAQ Therapeutics, a biotechnology company developing best- and first-in-class KRAS degraders for patients with lethal cancers lacking effective treatment options, today announced the completion...
SOLVE FSHD, a venture philanthropy organization committed to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today announced a $3 million investment in Armatus Bio,...
There are a lot of American startups funding deals that are creating buzz around the startup ecosystem. These are the growth-stage and early-stage deals of this week. Let’s talk about the Top 10 Funding deals.
Junevity, a biotechnology company on a mission to extend lifespan and healthspan by resetting cell damage from age-related diseases, announced $10 million in seed funding led by Goldcrest Capital and Godfrey Capital.
Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, announced the closing of a $200 million Series C financing led by New Enterprise Associates (NEA) with Foresite Capital joining the round and participation of existing investors including RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Sanofi Ventures, Pontifax, Mass General Brigham Ventures, New Leaf Ventures, funds managed by abrdn Inc., funds and accounts managed by BlackRock, Eurofarma Ventures, and Soleus Capital.
There are a lot of American startups funding deals that are creating buzz around the startup ecosystem. These are the growth-stage and early-stage deals of this week. Let’s talk about the Top 10 Funding deals.
VisiRose, a privately-held, clinical-stage biotechnology company developing novel ocular therapeutics, announced a $3 million seed financing round for VisiRose.
Aviceda Therapeutics (“Aviceda”), a private, clinical-stage biotech company announced the closing of a $207.5 million Series C financing. Proceeds will support the ongoing Phase 2b/3 and planned pivotal Phase 3 clinical trial for AVD-104 in geographic atrophy (GA), a vision-threatening condition secondary to advanced age-related macular degeneration, and the expansion into other ophthalmic indications.
Tenvie Therapeutics launched with a commitment to transform the treatment of neurological diseases. The company combines a deep and diverse portfolio of small molecule assets, including programs acquired from Denali Therapeutics Inc., with a proven team of research and development leaders.
